arznei-telegramm Logo a-t Kurzlogo
    ❮ a-t 4/2017 a-t ❯
    This is a translation of the table of contents. One article of each issue is translated and freely available.
    table of contents
    SPOT ON

    Amount of refund according to the AMNOG (Pharmaceutical Market Restructuring Act) – Higher Social Court questions calculation and cost effectiveness

    FOURIER study with evolocumab (REPATHA) – 2 million € per prevented event

    THERAPY FROM A CRITICAL VIEWPOINT

    Rivaroxaban for extended prophylaxis after thromboembolism?

    Are antibiotics unnecessary in uncomplicated diverticulitis?

    Bicalutamide (CASODEX 150 mg, generics) in PSA-recurrent prostate cancer after prostatectomy

    CURRENT ADR NETWORK REPORT

    Anisocoria with escitalopram (CIPRALEX, generics)
    free

    IN BRIEF

    Dabigatran (PRADAXA) versus warfarin (COUMADIN) for ablation in atrial fibrillation

    PRAC recommends suspension of marketing authorisations of four MRI contrast agents

    Finally – Servier ceases distribution of strontium ranelate (PROTELOS)

    FASTJECT lots recalled

    e a-t ON THE INTERNET

    France: 3rd and 4th generation contraceptives less and less prescribed

    arznei-telegramm

    Independent drug information – in English

    Concise, critical evaluations of drugs and medical devices for evidence-based therapy and patient advice on benefits and risks – independent, ad-free and funded exclusively by subscriptions.

    Browse free articles